(Q37122893)

18 August 2017

1 reference

title

Paradigm shifts in cancer vaccine therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6326176&resulttype=core&format=json

13 May 2020

1 reference

1 reference

1

Jeffrey Schlom

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6326176&resulttype=core&format=json

13 May 2020

2

James L Gulley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6326176&resulttype=core&format=json

13 May 2020

author name string

Philip M Arlen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6326176&resulttype=core&format=json

13 May 2020

publication date

28 March 2008

1 reference

Experimental Biology and Medicine

18 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6326176&resulttype=core&format=json

13 May 2020

volume

233

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6326176&resulttype=core&format=json

13 May 2020

page(s)

522-534

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6326176&resulttype=core&format=json

13 May 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6326176&resulttype=core&format=json

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

RECIST revisited: a review of validation studies on tumour assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

A clinical development paradigm for cancer vaccines and related biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Cancer vaccines: moving beyond current paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Lymphocyte therapy of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

The use of bisphosphonates in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

CTLA-4: new insights into its biological function and use in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Multiple costimulatory modalities enhance CTL avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Ex vivo identification, isolation and analysis of tumor-cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3181%2F0708-MR-226

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine

21 January 2018

1 reference

12 December 2020

A triad of costimulatory molecules synergize to amplify T-cell activation

1 reference

12 December 2020

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

1 reference

12 December 2020

Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas

1 reference

12 December 2020

Effect of 5-fluorouracil on carcinoembryonic antigen expression and shedding at clonal level in colon cancer cells

1 reference

12 December 2020

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

1 reference

12 December 2020

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma

1 reference

12 December 2020

Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen.

1 reference

12 December 2020

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

1 reference

12 December 2020

Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21

1 reference

12 December 2020

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

1 reference

12 December 2020

Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy

1 reference

12 December 2020

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

1 reference

12 December 2020

Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma

1 reference

12 December 2020

Future directions in tumor immunotherapy: CTLA4 blockade

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

Identifiers

DOI

10.3181/0708-MR-226

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6326176&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6326176&resulttype=core&format=json

13 May 2020

1 reference